Clinical trials: Atezolizumab
Advanced Solid Tumor
A Study of YL201 in Patients With Advanced Solid Tumors
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States.
- Trial name
- NCT05434234
- Testing
- YL201, YL201 and atezolizumab
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 312 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Carcinoma, Hepatocellular
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are…
- Trial name
- IMbrave050 (NCT04102098)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 134 sites in United States, Australia and 24 more
- Volunteers
- 668 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage…
- Trial name
- NEO-TIM (NCT04722575)
- Testing
- Cobimetinib 20 MG Oral Tablet, Vemurafenib 240 Mg Oral Capsule, Atezolizumab 1200 MG in 20 ML Injection
- Where
- 6 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Fondazione Melanoma Onlus
Hepatocellular Carcinoma
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare…
- Trial name
- LOST-B (NCT05537402)
- Testing
- Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
This trial will treat patients with platinum resistant ovarian, fallopian tube or primary peritoneal cancer as defined by a progression free interval within six months of completion of most recent platinum-based treatment with a…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor
- Trial name
- NCT05538091
- Testing
- Vismodegib, Atezolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Ronald Buckanovich
PD-L1-selected Solid Tumors
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected…
- Trial name
- SKYSCRAPER-11 (NCT05661578)
- Testing
- Tiragolumab and Atezolizumab IV FDC
- Where
- 32 sites in United States, China and 7 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Abemaciclib With or Without Atezolizumab for mCRPC
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic…
- Trial name
- NCT04751929
- Testing
- Abemaciclib, Atezolizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients.
- Trial name
- NCT05999812
- Testing
- all trans Retinoic Acid, Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Texas Southwestern Medical Center
Unresectable Hepatocellular Carcinoma
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and…
- Trial name
- AB7 (NCT04829383)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Howard S Hochster
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT03321643
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT04984811
- Testing
- efineptakin alfa, Atezolizumab
- Where
- 22 sites in United States
- Volunteers
- 33 people
- Sponsor
- NeoImmuneTech
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
This phase II trial studies how well atezolizumab, cobimetinib, and eribulin work in treating patients with inflammatory breast cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT03202316
- Testing
- Atezolizumab, Cobimetinib, Eribulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
The purpose of this study was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection…
- Trial name
- SKYSCRAPER-15 (NCT06267001)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 37 sites in Argentina, Australia and 9 more
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Gastric Adenocarcinoma, Metastatic Gastric Cancer
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
For patients with advanced/metastatic gastric adenocarcinomas in progression after a first line chemotherapy comprising platinum and fluoropyrimidine, the reported second line treatments are : 1) paclitaxel combined with…
- Conditions
- Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma
- Trial name
- IMMUNOGAST (NCT04739202)
- Testing
- Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab
- Where
- 8 sites in France
- Volunteers
- 54 people
- Sponsor
- Hospices Civils de Lyon
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer.
- Trial name
- NCT04334941
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 561 sites in United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
This phase II trial tests whether atezolizumab works to shrink tumors before surgery in patients with head and neck squamous cell cancer with an unknown or historic primary site that has spread to other places in the lymph nodes…
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT05110781
- Testing
- Atezolizumab, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Davis
Malignant Pleural Mesothelioma
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into…
- Trial name
- Immuno-MESODEC (NCT05765084)
- Testing
- Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Antwerp
Small Cell Lung Cancer
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in…
- Trial name
- NCT06771518
- Testing
- Thoracic radiotherapy, Atezolizumab 1200 mg e.v. q21
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- Regina Elena Cancer Institute